EU Clears NewAmsterdam's Cholesterol Pills in First Global Approval

The European Commission has approved NewAmsterdam Pharma Company N.V.'s (NASDAQ:NAMS) two oral cholesterol medicines, Ubeslo and Evlarco — the first global approvals for either product. The company announced the decision on September 21.

Ubeslo contains 10 mg of obicetrapib. Evlarco combines 10 mg of obicetrapib with 10 mg of ezetimibe. Both drugs lower low-density lipoprotein cholesterol, or LDL-C, the so-called bad cholesterol. The approvals cover adults with primary high cholesterol or mixed lipid disorders, with treatment eligibility depending on existing therapy and statin tolerance.

Menarini holds exclusive European commercialization rights. NewAmsterdam Pharma is entitled to tiered royalties ranging from low double-digit percentages to the mid-20% range on net sales in the licensed territory. The open question is how quickly an approved treatment becomes a meaningful source of recurring revenue.

The bull case

The clinical proposition pairs substantial cholesterol lowering with oral dosing. According to the approval announcement, Phase 3 studies showed statistically significant LDL-C reductions versus placebo of up to 40% for obicetrapib and approximately 50% for the ezetimibe combination. Those studies evaluated patients already receiving maximally tolerated cholesterol-lowering treatment.

That creates a practical opportunity among patients who need additional LDL-C reduction. A single tablet containing two medicines could simplify treatment for eligible patients who would otherwise take separate pills. Convenience may support adoption, though sustained use will depend on the patient experience and access.

NewAmsterdam also enters commercialization with an established partner rather than building a sales force from scratch. Menarini's cardiovascular expertise and European commercial infrastructure reduce that need. The royalty structure lets NewAmsterdam participate in sales growth through an existing network.

The agreement carries up to an additional €833 million in potential clinical, regulatory, and commercial milestone payments. Those payments hinge on specified achievements. Royalties, by contrast, offer the prospect of recurring income as prescriptions grow.

The balance sheet supports the transition. NewAmsterdam reported $678.3 million in cash, cash equivalents, and marketable securities as of June 30, 2026.

The bear case

Cholesterol reduction alone does not prove these products prevent heart attacks or strokes. The ongoing PREVAIL cardiovascular-outcomes trial, which enrolled more than 9,500 patients, is designed to test whether obicetrapib reduces major cardiovascular events. In its August update, NewAmsterdam planned an interim analysis for the fourth quarter of 2026, with results expected in the first quarter of 2027.

The stakes

The EU approvals give NewAmsterdam its first commercial foothold, but the royalty economics remain untested until Menarini reports early prescription data. The PREVAIL interim readout in early 2027 will likely determine whether obicetrapib becomes a cardiology mainstay or remains a lipid-lowering niche product.